6Gately S, Kerbel R. Antiangiogenic scheduling of lower dose cancer chemotherapy[J]. Cancer J, 2001,7(5) : 427-436.
7Suvannasankha A, Fausel C, Juliar B E, et al. Final report of toxicity and efficacy of a phase Ⅱ study of oral cyclophosphamide,thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A HoosierOncology Group Trial, HEM01-21 [ J]. Oncologist, 2007, 12(1 ) :99-106.
8Camps C, Massuti B, Jimenez A, et al. Randomized phase Ⅲ study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Group Trial [ J ]. Annals of Oncology, 2006,17 (3) :467-472.
9Tas F, Duranyildiz D, Soydine H O, et al. Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and throm- bospondin-1 levels in patients with advanced nonsmall cell lung cancer [ J ]. Cancer Chemother Pharmacol, 2008,61 (5) :721-725.
10Parkin D M, Bray F, Ferlay J, et al. Global cancer statistics, 2002 [ J ].CA Cancer J Clin, 2005,55 ( 2 ) :74-108.
